SIRTURO (bedaquiline fumarate)
DIARYLQUINOLINE ANTI-MYCOBACTERIAL ANTIBIOTICS·PULMONARY MULTI-DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS
JANSSEN PRODUCT
Indication
Pulmonary multi-drug resistant Mycobacterium tuberculosis
Pulmonary multidrug-resistant *Mycobacterium tuberculosis* is an airborne, infectious mycobacterial disease primarily targeting the respiratory system, specifically the lung parenchyma and tracheobronchial tree. Read more about Pulmonary multi-drug resistant Mycobacterium tuberculosis
3 drugs 3 manufacturers
Drugs that treat it
Common Pulmonary multi-drug resistant Mycobacterium tuberculosis therapies.
PRETOMANID
NITROIMIDAZOLE DERIVATIVES ANTI-MYCOBACTERIAL ANTIBIOTICS·PULMONARY MULTI-DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS
DEY LABS.
PRETOMANID
NITROIMIDAZOLE DERIVATIVES ANTI-MYCOBACTERIAL ANTIBIOTICS·PULMONARY MULTI-DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS
Viatris Specialty
Filter & compare in the drug finder →Opens the drug finder with Pulmonary multi-drug resistant Mycobacterium tuberculosis preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPulmonary multidrug-resistant *Mycobacterium tuberculosis* is an airborne, infectious mycobacterial disease primarily targeting the respiratory system, specifically the lung parenchyma and tracheobronchial tree.
It is microbiologically defined by infection with *Mycobacterium tuberculosis* isolates that demonstrate in vitro resistance to at least isoniazid and rifampin, the two most potent first-line antitubercular medications.
Pathophysiologically characterized by necrotizing granulomatous inflammation, the disease often leads to tissue destruction, pulmonary cavitation, chronic cough, hemoptysis, and progressive systemic decline, posing severe treatment challenges and high risks of treatment failure compared to drug-susceptible infection.
- who.int
Pulmonary multidrug-resistant *Mycobacterium tuberculosis* is an airborne, infectious mycobacterial disease primarily targeting the respiratory system, specifically the lung parenchyma and tracheobronchial tree It is microbiologically defined by infection with *Mycobacterium tuberculosis* isolates that demonstrate in vitro resistance to at least isoniazid and rifampin, the two most potent first-line antitubercular medications Pathophysiologically characterized by necrotizing granulomatous inflam...
- nih.gov
Pulmonary multidrug-resistant *Mycobacterium tuberculosis* is an airborne, infectious mycobacterial disease primarily targeting the respiratory system, specifically the lung parenchyma and tracheobronchial tree Pathophysiologically characterized by necrotizing granulomatous inflammation, the disease often leads to tissue destruction, pulmonary cavitation, chronic cough, hemoptysis, and progressive systemic decline, posing severe treatment challenges and high risks of treatment failure compared t...
- wikipedia.org
Pulmonary multidrug-resistant *Mycobacterium tuberculosis* is an airborne, infectious mycobacterial disease primarily targeting the respiratory system, specifically the lung parenchyma and tracheobronchial tree
- nih.gov
It is microbiologically defined by infection with *Mycobacterium tuberculosis* isolates that demonstrate in vitro resistance to at least isoniazid and rifampin, the two most potent first-line antitubercular medications
- cdc.gov
It is microbiologically defined by infection with *Mycobacterium tuberculosis* isolates that demonstrate in vitro resistance to at least isoniazid and rifampin, the two most potent first-line antitubercular medications
- cdc.gov
It is microbiologically defined by infection with *Mycobacterium tuberculosis* isolates that demonstrate in vitro resistance to at least isoniazid and rifampin, the two most potent first-line antitubercular medications
- nih.gov
Pathophysiologically characterized by necrotizing granulomatous inflammation, the disease often leads to tissue destruction, pulmonary cavitation, chronic cough, hemoptysis, and progressive systemic decline, posing severe treatment challenges and high risks of treatment failure compared to drug-susceptible infection
Personalize your experience
Follow Pulmonary multi-drug resistant Mycobacterium tuberculosis and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.